Surveillance and Epidemiology of Drug-resistant Infections Consortium
The Surveillance and Epidemiology of Drug-resistant Infections Consortium (SEDRIC) brings together a range of international experts to share expertise and take action to tackle the gaps in drug-resistant infection surveillance and epidemiology.
SEDRIC aims to transform the way countries are able to track, share and analyse information about the rise and spread of drug-resistant infections.
Better information will speed up action and improve public health interventions, saving many lives in the process.
identify the critical gaps in, and barriers to, the surveillance and epidemiology of drug-resistant infections, and how these can be overcome at a national and global level
provide technical expertise and knowledge to strengthen and support existing surveillance networks and activities
improve global co-ordination by helping countries adopt common and sustainable best practices and strategies
inform and shape Wellcome’s strategy for limiting the future impact of drug-resistant infections.
It began its work in January 2018 and is funded by Wellcome.
Board and working groups
The SEDRIC board has 12 members, with expertise spanning genetics, epidemiology, microbiology, public health and animal health. The current chair is Professor Sharon Peacock.
The board will commission reviews and convene fixed-term working groups to address key issues in the fight against drug-resistant infection. This could include how to develop guidelines and tools to encourage data sharing, or how to translate scientific evidence into policy.
Become a member
Would you like to help shape SEDRIC’s work? We’re looking for members to join the Consortium.
Applications are open to anyone who has an interest in any aspect of the surveillance and epidemiology of drug-resistant infections.